DGE invites life science Diversity, Equity & Inclusion (“DEI”) practitioners, health equity advocates, HR executives, and health policy leaders, to attend the 3rd Advancing Diversity, Equity & Inclusion in Pharma & Healthcare Summit to be held at the Hyatt Bellevue, Philadelphia, PA, on September 19-20, 2023. The industry’s leading event will focus on putting developing policies into practices including novel case studies and sessions on important areas.

The leading DEI event for Pharma & Healthcare serves as a dynamic platform for industry leaders, advocates, practitioners and influencers to convene, work toward common goals and drive the life science ecosystem toward positive change. Attendees will get the unique opportunity to meet with like-minded professionals, benchmark with peers and engage in thought-provoking discussions in the pursuit of an equitable and more inclusive future for all.

Featuring an exceptional blend of collaborative sessions, insightful presentations, and actionable strategies, this groundbreaking summit will leave an unforgettable mark on participants. They will engage in valuable panel discussions and gain information from keynote speakers who will share their unique strategies and experiences.

Advancing Diversity, Equity, and Inclusion

The summit will focus on the growing prominence of diversity and inclusion in clinical research and drug development. Expert-led sessions will explore the diverse patient populations in clinical trials while addressing differences in healthcare results.

Attendees will gain valuable insights into the challenges faced in implementing an effective DEI practice from the ground up as well as gathering cross-functional insights on DEI collaboration and the role of medical communications to address health inequities and disparities. In addition, the agenda will cover integrating DEI into talent recruitment, transforming organizational culture and utilizing change management. The event will also offer new case studies from Pfizer, Merck, Sanofi, Takeda and others. Formats will also include panel discussions such as the power of mentorship and ERGs.

The agenda will delve into the importance of actionable workplace culture that supports equity and inclusivity at all levels. The professionals from the pharma and healthcare industries will bring together different perspectives and strategies for improving DEI in the workplace as well as throughout the entire life science ecosystem most importantly with patients. The main focus will be to create industry-wide best practices and solutions that drive meaningful change throughout the industry that is viewed as a leader in diversity, equity and inclusion.

To learn more, please visit https://ibn.fm/S7hSF.

• BiondVax, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, was featured in a recent analyst report reiterating a Buy recommendation and a $70 target price
• The report discussed Eli Lilly’s announcement of a definitive agreement to acquire DICE Therapeutics for approximately $2.4 billion as evidence of the potential value of BiondVax in this segment of the therapeutics market
• DICE Therapeutics is currently evaluating its lead drug candidate, DC-806, an oral IL-17 inhibitor, in a Phase II trial, with early-stage results from the Phase I study showing a near-44% reduction in Psoriasis Area and Severity Index
• The report noted that the deal between Eli Lilly and DICE Therapeutics illustrates the potential valuation that BiondVax could receive with positive early-stage clinical results
• Also, revenues from FDA-approved psoriasis drugs show the potential value of the company should its IL-17 NanoAb therapy eventually receive FDA approval

According to Goldman Sachs Research, the global pharmaceutical industry is sitting on about $700 billion in dealmaking firepower, expected to fuel M&A-driven growth as companies look to revamp their intellectual property portfolio as their existing patents expire (https://ibn.fm/7VNq6). Flush with cash, big drugmakers also have easy access to alternative financing, factors that allow them to make aggressive acquisition bids for promising biotechnology companies and other targets (https://ibn.fm/Uo69R).

This played out recently when Eli Lilly and Company (NYSE: LLY) announced it had signed a definitive agreement with DICE Therapeutics, Inc. (NASDAQ: DICE) to acquire DICE (https://ibn.fm/CPCbR) in a deal valued at approximately $2.4 billion. DICE is a biopharmaceutical company that develops novel oral therapeutic candidates – such as DC-806 and DC-853, both oral interleukin-17 (“IL-17”) inhibitors – currently in clinical development to treat chronic immune system diseases.

The pending acquisition formed the basis of analysis by Aegis Capital Corp., which underlined that the recent M&A activity shows the potential value of BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products. Aegis, therefore, reiterated its Buy recommendation and a $70 target price on BiondVax (https://ibn.fm/wHmf2).

Aegis’ coverage followed BVXV’s June announcement that it had signed an exclusive worldwide license with the Max Planck Society and University Medical Center Göttingen (“UMG”), both in Germany, to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for all potential indications, starting with psoriasis and psoriatic arthritis (https://ibn.fm/5bpWM).

“The license of the IL-17 NanoAb from Max Planck is not only an exciting opportunity to develop a unique treatment for psoriasis and other autoimmune diseases, but also another validation of the productivity of our collaboration with Max Planck and UMG and portends additional significant developments to follow,” BiondVax CEO Amir Reichman said at the time. 

IL-17 is a family of immune system cytokines that comprises six isoforms (IL-17A to IL-17F). And while the IL-17 pathway is known to contribute to defenses against extracellular bacteria and fungi, it also plays a significant role in originating and feed-forwarding the inflammatory cycle of psoriasis (https://ibn.fm/I1Vqe). Psoriasis is a chronic autoimmune disease that causes inflammation and scaling of the skin. According to the National Psoriasis Foundation, about 8 million people in the U.S. and 125 million worldwide suffer from the condition (https://ibn.fm/sU999).

Given the causative role of IL-17, IL-17 inhibitors, most of which belong to a family of biological drugs called monoclonal antibodies (“mAbs”), are used to treat psoriasis. Chemically, these mAbs bind to the IL-17A cytokine, inhibiting interaction with the IL-17A receptor. However, “the latest and most effective mAbs for the treatment of plaque psoriasis that are currently marketed, as well as those that, to BiondVax’s knowledge, are under clinical development by other companies, target not only IL-17A but also IL-17F and IL-17A/F complex,” wrote the company in the June press release.

DICE’s lead drug candidate, DC-806, which is currently being evaluated in a Phase II study involving participants with moderate to severe plaque psoriasis, targets the IL-17A (https://ibn.fm/V70Fo). Early-stage results released last October nonetheless showed that the drug candidate led to a mean percentage reduction in Psoriasis Area and Severity Index (“PASI”) of up to about 44% compared to 13.3% for placebo. BiondVax’s NanoAbs exhibit several ‘biobetter’ qualities compared to mAbs and IL-17 inhibitors like DC-806, including better patient safety and convenience.

Little wonder that Aegis noted in its report, “This deal between Eli Lilly and DICE Therapeutics illustrates the potential valuation that BiondVax could receive if it has positive early-stage clinical results.” So far, several factors tip the scale in BiondVax’s favor. First, the company is focusing on a condition for which the mechanism of action of existing antibody-based treatments is well understood and has, in fact, been validated through clinical trials that have resulted in FDA approval. Secondly, a preclinical in vivo proof-of-concept study evaluating the company’s anti-COVID-19 NanoAb therapy virtually eliminated the virus from the lungs, caused milder and shorter illness, and had prophylactic properties. While the study evaluated an anti-COVID-19 drug, it showed, at least early on, the capabilities of NanoAbs.

Furthermore, should BiondVax eventually receive FDA approval for its anti-IL-17 NanoAbs, precedent exists showing that the company and its shareholders stand to gain significantly from the potential market demand. Of the three IL-17 inhibitors currently approved by the FDA, Cosentyx (secukinumab) by Novartis Pharmaceuticals Corp. delivered $4.8 billion in sales in 2022, up 5% year over year (https://ibn.fm/TBPVP), while Taltz (ixekizumab) by Eli Lilly generated $2.482 billion in 2022, up from $2.213 billion in 2021 (https://ibn.fm/nHncH). (Sales data from the third drug, Saliq (brodalumab) by Bausch Health, are not publicly available.)

Even with the enormous potential of BiondVax’s anti-IL-17 NanoAbs, the company is committed to developing a pipeline of diversified and commercially viable products and platforms, providing broad based and diversified opportunities for success. In addition to psoriasis and psoriatic arthritis, the company is targeting treatments of diseases with unmet medical needs and attractive commercial opportunities, including asthma, macular degeneration, and COVID-19.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• Lexaria’s patented DehydraTECH(TM) technology enhances the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats
• This unique approach to drug delivery has earned Lexaria a total of 35 patents, with many patents pending worldwide
• The company continues active discussions with multi-billion dollar companies for the potential use of DehydraTECH in their commercial pursuits
• Lexaria is also actively seeking commercial partners during 2023 and 2024

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is out on an ambitious move to address conditions with high unmet needs. This focus has allowed them to make strides in the potential treatment of conditions such as hypertension, epilepsy, human hormone delivery, and nicotine replacement; all made possible through its patented technology, DehydraTECH(TM).

DehydraTECH enhances the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats. The technology serves as an additional step that can be easily incorporated into any formulation and manufacturing process, allowing for speedy delivery, an increase in bioavailability, and an increase in brain absorption, among other advantages (https://ibn.fm/Cr9r8).

Lexaria’s studies have demonstrated a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,700 percent, which has opened the technology up to new possibilities for improved drug delivery.

One stand-out feature of DehydraTECH is its ability to work symbiotically with existing physiological systems to enable masking oral and olfactory receptors, rendering DehydraTECH-processed compounds mostly flavorless and odorless. This results in formulations not requiring sweeteners or chemical masking agents for flavor and odor blocking, meaning that manufacturers can create low-sugar products with fewer calories while avoiding excessive artificial sweeteners.

Once ingested, the compounds, through the help of fatty acids, permeate the intestinal wall for the active payload, then are transported to the systemic circulation by one of two pathways, typically dependent on the type of fatty acid(s) chosen for a given formulation. For hepatic transport, or where liver metabolism is desirable for biotransformation of the payload, Lexaria’s methodology uses medium-chain fatty acids. For lymphatic transport, on the other hand, Lexaria uses long-chain fatty acids, which are absorbed via the lymphatic lacteals, ultimately diverting them away from the liver and entering the general circulation very quickly.

DehydraTECH and its unique approach to drug delivery have earned Lexaria a current total of 35 patents across the United States, Canada, Mexico, Australia, Japan, India, and the European Union. Although it has already achieved considerable intellectual property protection through its existing patent portfolio, the company has a number of additional patents pending worldwide. These achievements have sparked interest across various industries. Lexaria’s CEO, Chris Bunka, has noted the company’s active discussions with multi-billion dollar companies for the potential use of its technology in their commercial product pursuits.

“Our applied R&D is paying off in spades because we are currently in active discussions with several multi-billion dollar companies around the world for the potential use of Lexaria’s DehydraTECH technology in their commercial product pursuits,” noted Mr. Bunka.

“These discussions are ongoing and have thus helped us to meet one of our primary objectives of the last year, which is to introduce DehydraTECH to world-leading potential collaborators,” he added (https://ibn.fm/l2zam).

Lexaria is ambitious in its push for DehydraTECH and is currently seeking commercial partners to use the technology in what are usually multi-billion-dollar markets. The company is taking steps to have multiple choices in how to fund its operations, and so far, it is on track to have 2023 as its best year ever.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• D-Wave is working with a portfolio of impressive commercial customers including Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, and many more
• Governments worldwide are calling for the implementation of quantum applications – with the United States pushing for development and deployment of quantum applications within the next 24 months
• D-Wave, the world’s first commercial quantum computing solutions supplier, is successfully filling the increasing quantum needs of customers along with the growing interest of the government for expanding quantum technology

D-Wave Quantum (NYSE: QBTS), a leader in commercial quantum computing systems, software, and services, continues to provide customers clear value via practical quantum and quantum-hybrid applications that solve real-world problems in the areas of logistics, artificial intelligence, materials sciences, drug discovery, scheduling, and financial modeling. The company delivers these applications to a portfolio of blue-chip industry leaders that include Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, and more – reflecting the growing interest and adoption of today’s quantum annealing technology among forward-looking companies.

D-Wave’s quantum technology has been applied to a multitude of computationally complex problems, from grocery store optimization to protein design. Groovenauts and Mitsubishi Estate utilized quantum annealing to optimize waste collection and reduce carbon dioxide emissions by 57% (https://ibn.fm/vxRnH). Pattison Food Group reduced the time of important grocery optimization tasks from 25 hours to two minutes using D-Wave’s quantum technology (https://ibn.fm/9HH8Y). Sigma-i streamlined personnel management through quantum computing (https://ibn.fm/oWbjp).

As awareness of quantum annealing’s value to the enterprise grows, D-Wave is also providing resources to streamline adoption. It designed the Launch™ program to help enterprises accelerate the quantum journey by facilitating the transition from problem discovery to production implementation. The company’s in-house professional services teams and technical domain experts help customers start their first quantum project and drive application development through to real-world production implementation.

Various forward-thinking organizations see quantum as an opportunity to move ahead of the competition. According to Hyperion Research, 80% of early adopters plan to increase their commitment to quantum in the next two to three years (https://ibn.fm/RBgMA). Governments worldwide are also pushing for the implementation of quantum applications – with the United States pushing for development and deployment within the next 24 months.

D-Wave Quantum recently announced that it had regained listing compliance with the New York Stock Exchange (“NYSE”), meeting its continued listing standard for the minimum share price. On July 3, 2023, the NYSE provided D-Wave with a notification letter of recompliance based on the company’s minimum share price being at least $1.00 on June 30, 2023, and a calculation of the average closing price for 30 trading days that reflected the $1.00 minimum requirement on the applicable dates. D-Wave will continue to be traded on the NYSE, subject to all applicable listing standards (https://ibn.fm/MIFh2).

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, which are subject to a number of risks. Forward-looking statements in this article include, but are not limited to, statements regarding the release and performance of the Advantage2 processor. We cannot assure you that the forward-looking statements in this article will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including general economic conditions and other risks; customer acceptance of our products and services; and the uncertainties and factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement on Form S-1 filed by the Company with the SEC on February 13, 2023, as well as factors associated with companies, such as D-Wave, that are engaged in the business of quantum computing, including anticipated trends, growth rates, and challenges in those businesses and in the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; changes in applicable laws and regulations; the effect of pandemics, geopolitical events, natural disasters, wars, or terrorist acts on our business or the economy in general; and the impact of inflation. Furthermore, if the forward-looking statements contained in this article prove to be inaccurate, the inaccuracy may be material. In addition, you are cautioned that past performance may not be indicative of future results. In light of the significant uncertainties in these forward-looking statements, you should not place undue reliance on these statements in making an investment decision or regard these statements as a representation or warranty by any person we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this article represent our views as of the date of this article. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this article.

• Report projects that demand for nickel from the battery industry is set to increase significantly
• Texmont testing delivers results that meet or exceed expectations
• The company has acquired 403 additional mining claims within the Texmont ultramafic trend

With experts predicting that nickel metal will play a key role in the 2023 battery-grade market (https://ibn.fm/e8Ky4), Canada Nickel Company (TSX.V: CNC) (OTCQX: CNIKF) appears to be ideally positioned in the growing space. The company just released initial results from preliminary metallurgical testing at its Texmont Nickel Sulphide Project, and the results meet or exceed historical results (https://ibn.fm/NpwuL).

Nickel metal has a key role to play in 2023 battery grade market, states a recent Fastmarkets report. “With global lithium-ion battery production forecast to grow significantly in the coming years, market participants in the global nickel industry are working on the most efficient way to produce nickel sulfate for lithium-ion battery cathodes,” the article notes. “In addition, nickel sulfate is a key component in nickel-manganese-cobalt (“NMC”) units, and nickel-rich batteries are often preferred over lithium-ion batteries due to their high energy density and longer range when used in electric vehicles (“EVs”).

“Demand for nickel from the battery industry is, therefore, set to increase significantly,” the report continued. “Fastmarkets researchers forecast that demand for nickel for use in EV batteries represents around 280,000 tonnes per year of nickel metal globally, which corresponds to around 10% of worldwide demand for nickel. vBut this figure is set to grow significantly. Demand from the battery industry is expected to increase to close to 314,000 tonnes in 2023 and to 668,000 tonnes by 2025.”

With that projection as a backdrop, Canada Nickel’s report of nickel recoveries of 79% to 84% couldn’t have come at a better time. “Texmont continues to deliver excellent results, with initial metallurgy yielding nickel and cobalt recoveries and concentrate grades exceeding our expectations,” said Canada Nickel CEO Mark Selby. “Further, these results were achieved with a simple flowsheet, which will maximize potential opportunities to toll mill our initial production. I look forward to the next phases of work while we complete our initial resource on Texmont and complete a Preliminary Economic Analysis (‘PEA’) by year-end.”

Canada Nickel’s Texmont property is a past-producing mine that contains a large ultramafic body. The company has identified a near-surface, high-grade zone of less than 1% nickel wrapped within a moderate-high grade zone of 0.6 to 1.0% nickel, and Canada Nickel management is evaluating the potential for near-term production from Texmont through open pit mining of this moderate-high grade material. The company is planning to finalize the metallurgical flowsheet in the coming months, including conducting locked cycle and metallurgical variability tests. Following that, Canada Nickel anticipates releasing recovery equations for the Texmont PEA by the end of 2023.

In addition, the company announced that it has acquired 403 additional mining claims within the Texmont ultramafic trend through a series of purchase and sale agreements. “Given our success at Texmont, we capitalized on the opportunity to acquire regional mining claims, consolidating 20 kilometres of property with the potential to find more Texmont-style deposits,” Selby stated. “We have signed a total of 10 agreements, which consolidate 9,520 hectares of mining claims. We view this as an important and highly prospective addition to our Timmins Nickel District.”

Canada Nickel Company is advancing the next generation of nickel-sulphide projects to deliver nickel required to feed the high-growth electric vehicle and stainless-steel markets. Canada Nickel Company is pursuing the development of processes to allow the production of net zero carbon nickel, cobalt and iron products. The company provides investors with leverage to nickel in low political-risk jurisdictions. Canada Nickel is currently anchored by its wholly owned flagship Crawford Nickel-Cobalt Sulphide Project in the heart of the prolific Timmins-Cochrane mining camp.

For more information, visit the company’s website at www.CanadaNickel.com. 

NOTE TO INVESTORS: The latest news and updates relating to CNIKF are available in the company’s newsroom at https://ibn.fm/CNIKF

• Freight Technologies (aka Fr8Tech) is a growing commercial freight transportation technology developer whose flagship Fr8App platform helps shippers and carriers easily match loads and destinations in the USMCA
• Trucker Tools is a trip planning, shipment visibility, predictive freight matching and automated booking solutions company that has developed its flagship Smart Capacity(R) platform
• Fr8Tech recently announced integration of Trucker Tools’ network, boosting the pool of truck drivers able to use Fr8App by more than 315,000 carriers
• The collaboration is expected to increase the offers on loads by 75 percent and grow the carrier network for loads originating from and destined to locations within the United States by as much as twentyfold

Supply chain innovator Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) has expanded the reach of its modern technology platform by welcoming an extensive new pool of truck drivers working within the United States-Mexico-Canada Agreement (“USMCA”) trade area, increasing the ability of commercial freight transportation networks to manage shipping loads of all sizes.

Freight Technologies, aka Fr8Tech, recently announced completion of its collaboration with automated booking solutions platform Trucker Tools, integrating Trucker Tools’ extensive network of over 315,000 carriers across the United States with Fr8Tech’s load-matching solution Fr8App (https://ibn.fm/sPSOl).

Fr8App streamlines the process of connecting shippers with carriers within the USMCA (formerly NAFTA), both domestically and across international borders, using artificial intelligence (“AI”) and machine learning technology.

Fr8App makes it simpler for businesses to post notice of their product load and destination needs, and for truck drivers to view and instantaneously bid on those available loads if the rate aligns with the target, helping the marketplace to efficiently move commerce with trucks filled to a maximum capacity.

Fr8App and the suite of companion brands produced by Fr8Tech further empower shippers and carriers by helping them to easily track loads in real time as they are moving over the road, complete necessary documentation, find dedicated truck services, and transparently review truck operations, helping to eliminate costly errors.

“Fr8App delivered cross-border capacity during a difficult time for us as we worked first through the COVID-19 pandemic and then through our plant expansion challenges in Mexico and many times under conditions that others in the logistics industry were not willing to accept,” multinational insulation manufacturer K-FLEX de México SA de CV President Maged Anis stated recently after renewing the company’s contract with Fr8Tech (https://ibn.fm/vrfJm).

The collaboration between Fr8Tech and Trucker Tools is expected to increase the offers on loads by 75 percent and grow the carrier network for loads originating from and destined to locations within the United States by as much as twentyfold, according to the recent announcement.

For more information, visit the company’s website at www.Fr8Technologies.com and its freight matching platform information site at www.Fr8.app.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

• McEwen just reported new copper assays at its Los Azules project in San Juan, Argentina, the 9th largest undeveloped copper deposit in the world
• These results lead the company closer to realizing the full extent and economic potential of the deposit
• The latest drilling program, which began in October 2022 and concluded on June 19, 2023, has attracted new investment capital at rates implying a significant boost in the company’s value
• McEwen’s management is confident a future mine would support annual production of 415 million pounds of copper during its first 13 years at Los Azules, while creating long-term and sustainable value for its shareholders and all stakeholders

McEwen Mining (NYSE: MUX) (TSX: MUX), an asset-rich, diversified gold and silver producer in the Americas, on July 12th reported additional copper assays at its Los Azules project in San Juan, Argentina. Recent infill and other resource drilling completed since the data cut-off for the 2023 Preliminary Economic Assessment (“PEA”) highlights the strength of the resource model by directly comparing new assay results to the resource model prediction for the same area. A high level of predictability in the resource model represents an important milestone for McEwen and its efforts towards tapping into this vast resource (https://ibn.fm/qGfzj).

Over the course of the latest drill program, which began in October 2022 and concluded on June 19, 2023, up to 15 rigs completed some 39,900 m of drilling in 138 holes and have expanded the overall drill hole database to 126,000 m. Each hole serves to evaluate and de-risk geotechnical, hydrological, resource or exploration-related parameters and opportunities on a deposit whose depth and lateral extent has yet to be fully determined.

Preparations are underway for the next phase of drilling, which is expected to kick-off in early October. This phase will build on the progress made thus far and continue to increase geologic certainty with drilling needed to delineate a measured mineral resource estimate on the material expected to be mined in the first five years of operations. This work will support completion of a Feasibility Study (“FS”) in 2024/25 and could lead to a construction decision that would achieve the annual production of 415 million pounds of copper for the initial 13 years as contemplated in the 2023 PEA. This will be equivalent to supplying copper to 2.2 million electric vehicles annually.

With Los Azules ranked as the 9th largest undeveloped copper deposit in the world by Mining Intelligence (2022), McEwen Mining stands to emerge as a leader showcasing mining’s innovative contribution to the green economy while creating exceptional value for its shareholders. Recent investments by Stellantis, one of the world’s largest automakers and mobility providers and also Nuton LLC, a Rio Tinto venture, serve as international recognition of the long-term potential of the Los Azules project.

For more information, visit the company’s website at www.McEwenMining.com.

NOTE TO INVESTORS: The latest news and updates relating to MUX are available in the company’s newsroom at http://ibn.fm/MUX

• The article covers the concentration of cannabidiol in hypertensive women and men using the company’s patented DehydraTECH(TM)-processed CBD
• The global cardiovascular drugs market is expected to grow from $146.51 billion in 2021, reaching $173.48 billion in 2026, growing at a CAGR of 3.1%
• The article supports Lexaria’s efforts as it pursues IND status from the FDA for DehydraTECH-CBD as a potential treatment for hypertension
• Company is planning to begin preparations for a clinical trial that could start as early as the fourth quarter

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that its groundbreaking research utilizing its patented DehydraTECH(TM)-processed cannabidiol (DehydraTECH-CBD) has been published in eight peer-reviewed articles across six different publications. Lexaria’s research into DehydraTECH-CBD is being considered for indications including hypertension, diabetes, epilepsy, and more. Hypertension, heart disease, and diabetes are broad fields of interest for the company, with DehydraTECH-CBD generating positive pilot-study data.

“We’re proud of the impressive amount of research that our Company has been able to develop through its HYPER-H21 series of clinical studies that has now been assessed by a variety of our respected peers,” said John Docherty, President of Lexaria (https://ibn.fm/3SiWY). “Lexaria is establishing itself as one of the world’s leaders in the investigation of cannabidiol for the purposes of controlling human blood pressure, and we are now focused on launching an FDA-registered IND program to formally investigate DehydraTECH-CBD for hypertension this year.”

The global cardiovascular drugs market is expected to grow from $146.51 billion in 2021, reaching $173.48 billion in 2026, growing at a CAGR of 3.1%. The market’s growth is supported by the increase in sedentary jobs, busy lifestyles, and changing consumer preferences – factors affecting the disease profile in world populations. North America contributed as the largest cardiovascular drug region in 2021 (https://ibn.fm/wnBEH).

The most recent publication in June 2023 in the peer-reviewed International Journal of Molecular Sciences is “Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study” (https://ibn.fm/3syrx). The addition of this research article builds on the growing body of peer-reviewed literature developed by Lexaria’s leading research team into the effects of DehydraTECH-CBD and human health.

The findings and conclusions from the most recently published article revolve around the concentrations of CBD in a subject’s plasma and the bioavailability of the drug, examining the potential therapeutic benefits of CBD in the triple-blind study. Of the 62 hypertensive volunteers, concentrations of CBD were found to be higher in women and correlated with the proportion of adipose tissue. Lexaria found that the difference between the sexes was attributed to higher levels of fat tissue in women compared to men, and the men’s higher metabolism contributed to lower levels of CBD during the study.

Lexaria’s patented DehydraTECH technology improves how active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble molecules. DehydraTECH is covered by 34 granted patents and many pending patents.

The benefits of using DehydraTECH technology include:

• Improves the speed of onset, with effects felt in minutes
• Increased bioavailability by more effectively delivering the drug into the bloodstream
• Increased brain absorption, with testing suggesting up to 17x improvement
• Reduction in drug administration costs through a higher ratio of drug delivery

Lexaria’s next steps for its hypertension program include IND submission and additional preparations for its clinical trial. If the FDA clears the IND, Lexaria could begin its Phase Ib study as early as the fourth quarter of this year.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Digital money is replacing physical cash and further supporting the growth of a growing cashless society driven by the pandemic and other factors
• FEXD supports the United Nations’ Sustainable Development Goals of reducing cross-border transaction costs from 7 percent to 3 percent
• FEXD plans to offer a diverse portfolio of products and services to consumers and businesses in the United States, South Asia, East Asia, Africa, Europe, and Latin America

Financial technology, more commonly referred to as fintech, fuels economic growth and reduces inequality, poverty, and informality in underdeveloped companies. For impoverished people and small businesses without access to financial services as simple as a bank account, fintech creates opportunities and the ability to send and receive payments securely and access to savings, credit, and insurance products. Fintech Ecosystem Development (NASDAQ: FEXD), a special purpose acquisition company (“SPAC”), was formed with the mission of creating and growing a global financial services ecosystem to address unmet mobile money needs in developing and industrialized countries and markets.

With digital money replacing physical cash, consumers buy products and services from anywhere in the world, making payments across borders. FEXD plans to offer a diverse portfolio of products and services to consumers and businesses in the United States, South Asia, East Asia, Africa, Europe, and Latin America – using a growth strategy that includes developing mobile transaction platforms, applications, and services to help implement the changing financial landscape.

Mobitech International LLC (dba Afinoz), an artificial intelligence-enabled digital lending platform used by India’s leading banks, non-banking financial companies, and fintech loan providers, is currently a targeted acquisition for FEXD. Afinoz’s fintech platform supports enterprises making loans primarily to middle- and working-class borrowers via its website or mobile phone app. This platform makes loans available and affordable to millions of Indian workers and unbanked users by providing access at a low cost from more than 50 lending partners.

A McKinsey & Company research report outlines major trends driving the growth of digital payments worldwide, especially in the emerging markets that FEXD plans to service. The first trend outlined in the report is the pandemic, which accelerated the trend of contactless payments. Second, ecommerce continues to grow and evolve, being expected to increase by 12 to 15 percent annually by 2025. Third, governments are pushing for cashless payments to facilitate inoperability, plug tax leakages, and ensure effective aid distribution. Finally, the report points out that investors are hungry for digital payments, leading to an abundance of payments-focused fintechs (https://ibn.fm/HHUHb).

With so many areas of the world severely underserviced by financial service markets, FEXD plans to make it easier for people to access faster and cheaper ways of transferring money directly across borders to fund business transactions and provide support. With the increased interest in smartphone operation, mobile money platforms provide a solution for those who want to access financial institutions without requiring access to physical banking facilities. The company also allows people in other countries to access USD online accounts with FDIC assurance.

FEXD supports the United Nations’ Sustainable Development Goals of reducing cross-border transaction costs from 7 percent to 3 percent – using advanced technology to lower fintech costs and international fees. The company is led by a management team with extensive expertise in developing and managing financial service platforms and applications that will further drive the mobile money sector toward a cashless society.

For more information, visit the company’s website at www.FintechEcoSys.com.

NOTE TO INVESTORS: The latest news and updates relating to FEXD are available in the company’s newsroom at https://ibn.fm/FEXD

• National awareness of glioblastoma tumors (“GBM”) sustained by Congressional leaders aim to improve efforts to treat brain cancers and ultimately improve patient survival
• GBM is a widely occurring, aggressive and effectively incurable brain cancer that few patients survive beyond three years
• U.S.-based drug developer CNS Pharmaceuticals is in the midst of a global potentially pivotal clinical trial for its lead pharmaceutical candidate, Berubicin, which it aims to show improves on standard of care chemotherapy agent Lomustine’s approach to treating GBM
• Berubicin is a novel anthracycline that is practically unique in its ability to cross the blood-brain barrier to directly target tumors, and a Phase I trial of the drug in 2006 produced a surviving patient with over 15 years cancer-free
• An interim futility analysis of the current trial is anticipated later this year

A simple search of the Internet shows a number of clinical trials attempting to improve treatment options for glioblastoma (“GBM”) brain cancers, and Congress will recognize a National Glioblastoma Awareness Day next month to further support development of effective brain cancer responses.

That’s because, as the U.S. Social Security Administration acknowledges in its protocols for speeding disability applications through “compassionate allowances,” GBM tumors are “the most malignant of the primary brain cancers” and they respond “poorly to all currently available treatments.”

The protocols for compassionate allowance in GBM cases further note that “prognosis is grim, as most patients die within 2 years and few survive longer than three years” (https://ibn.fm/GhhSL).

Texas-based cancer drug innovator CNS Pharmaceuticals (NASDAQ: CNSP) is nearing the release of its interim analysis for its potentially pivotal clinical trial tracking the effectiveness of drug candidate Berubicin, which has already produced one patient with over 15 years of GBM survival.

Berubicin distinguishes itself by being virtually unique in its status as a cancer-fighting anthracycline that crosses the blood-brain barrier to attack central nervous system tumors directly.

Berubicin also distinguished itself by presenting statistically significant improvement in nearly half of the two dozen patients evaluated in a Phase I trial in 2006, including one patient whose last-known status remained cancer free as the current trial process began ahead of the COVID-19 pandemic.

The American Association for Cancer Research recently highlighted the case of GBM patient Adam Hayden, who has survived his diagnosis since 2016 — a decade less than the Berubicin trial patient but highly noteworthy nonetheless at seven years. 

Hayden’s role as a patient advocate led to an audience with Congressional leaders in May in which he and his family lobbied the lawmakers for increased funding for cancer research, as well as his participation in President Joe Biden’s Cancer Moonshot initiative at the White House (https://ibn.fm/iPbfm).

A bipartisan Congressional resolution designated last month as Brain Tumor Awareness Month in support of efforts to find better brain cancer treatments, and Arizona senior Sen. Kyrsten Sinema co-introduced bipartisan legislation designating July 9 as National Glioblastoma Awareness Day in honor of the late Arizona Sen. John McCain, who died of GBM in 2018.

Sinema’s resolution “calls for treatments of glioblastoma and related brain cancers to slow its progression, improve quality of life, and recognize the importance of molecular biomarker testing to improve diagnosis and treatment” (https://ibn.fm/gRvBo).

CNS Pharmaceutical has raised sufficient capital to enable the company to secure its trial beyond the interim analysis at least into the fourth quarter (https://ibn.fm/aWCfQ).

Primary completion of the trial is expected next year, with final results in late 2024 or early 2025. The trial has achieved global status, recruiting patients in the United States, Spain, France, Switzerland and Italy. The trial’s ultimate aim is to show Berubicin offers a better rate of overall survival compared to Lomustine, but there are also several secondary measurements that will be evaluated, including improved survival without tumor progression or adverse treatment events, and improvement in the overall proportion of patients responding to treatment.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP